Dissecting the tRNA Fragment tRF3E-Nucleolin Interaction: Implications in Breast Cancer.

Area of Science:

• Molecular biology
• Cancer research
• RNA biology

Background:

• Nucleolin (NCL) is a key RNA-binding protein implicated in cancer, particularly breast cancer.
• NCL dysregulation makes it a promising therapeutic target, but its RNA interactions are poorly understood.
• Tumor-suppressive tRNA fragments (tRFs) like tRF3E can interact with NCL.

Purpose of the Study:

• To elucidate the molecular mechanisms of the interaction between nucleolin (NCL) and the tumor suppressor tRNA fragment tRF3E.
• To investigate the role of NCL-RNA binding cooperativity in tRF3E's antitumor functions.
• To evaluate tRF3E as a potential NCL-targeted therapeutic agent for breast cancer.

Main Methods:

• Electrophoretic Mobility Shift Assays (EMSA) to study RNA-protein binding.
• In silico docking analysis to model the tRF3E-NCL complex.
• Functional assays in MCF7 breast cancer cells to assess tRF3E's biological activity.

Main Results:

• NCL binds two tRF3E molecules simultaneously via its RNA-binding domains (RBDs), forming a stable complex.
• A mutated tRF3E (M19-24) disrupts this cooperative binding, interacting only with a subset of NCL's RBDs.
• Wild-type tRF3E significantly inhibits breast cancer cell proliferation and colony formation, while the M19-24 mutant loses this function.

Conclusions:

• Cooperative binding between NCL and tRF3E is crucial for tRF3E's tumor suppressor activity in breast cancer.
• Understanding the NCL-tRF3E interaction dynamics provides a basis for developing novel NCL-targeted therapies.
• tRF3E shows promise as a potential biodrug candidate for breast cancer treatment.